Opendata, web and dolomites

ONCOTECT SIGNED

Early detection of tumor DNA in liquid biopsies as a biomarker of cancer recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOTECT project word cloud

Explore the words cloud of the ONCOTECT project. It provides you a very rough idea of what is the project "ONCOTECT" about.

ground    methodology    bv    considerable    lower    start    treatment    care    sequencing    detect    detection    time    screening    unable    dutch    feasibility    competing    reliably    diagnostic    remission    proprietary    ct    vitro    types    superior    strategy    detects    circulating    relative    licensing    monitoring    recurrent    disease    detecting    programs    blood    liquid    full    first    sme    gene    freedom    initial    obtain    neck    commercialization    breaking    ultra    patients    death    opportunity    proof    market    standard    lesions    rates    dna    survival    90    oncotect    recurrence    diagnostics    cyclomics    accurate    cancer    delays    company    radiological    cohort    regulatory    faster    quality    vision    genes    tumor    oncogenic    routine    critical    assay    ivd    carry    biopsies    sensitive    examination    decision    kit    mutations    underlying    encompassing    ambition    disrupt    fast    head    fto    samples    spectrum    leveraging    operate    inexpensive    hnc    integration    workflow    tp53    clinical   

Project "ONCOTECT" data sheet

The following table provides information about the project.

Coordinator
CYCLOMICS BV 

Organization address
address: MOSKEEPLEIN 82
city: UTRECHT
postcode: 3531 BX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.cyclomics.com/technology.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYCLOMICS BV NL (UTRECHT) coordinator 50˙000.00

Map

 Project objective

Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies). The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods. Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More